Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients. - Wikidata - awgldk - TriplyDB

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

http://www.wikidata.org/entity/Q37734245

about

Deferasirox: Over a Decade of Experience in Thalassemia

P2860

Q58701123-055AD82D-C0F0-4A0E-9374-7238E2EA6123

P2860

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

http://www.wikidata.org/entity/Q37734245

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@en

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@nl

type

label

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@en

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@nl

prefLabel

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@en

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@nl

P1433

Q37734245-D08ABE58-E174-4218-9B84-F2AC88FFF310

P1476

Q37734245-58927823-972B-490F-AC66-EAE829B1E0AA

P2093

Q37734245-34BD56D3-53C2-43E9-93A7-880168321133

Q37734245-802F4299-0F60-4637-A746-187E47A9AF89

Q37734245-87F804F4-0E2E-40F7-9944-9D6832B5B471

Q37734245-A8AAAD71-D927-4D40-AD36-E685877CD99A

Q37734245-ADFD430B-8076-44CA-A6A0-A641D73EA449

Q37734245-C7523778-8555-4992-BA59-FE62CBCC00DC

Q37734245-E22F3F88-9919-4F7C-BBF1-A84D27DD015C

Q37734245-E288DDAD-9B2B-4D22-93CB-7CB79A650E99

P2860

Q37734245-0BFEAA73-B510-4AB1-A4FC-E595045A6DAF

Q37734245-0E465BF6-A1ED-4402-BC1F-D094A54B81FF

Q37734245-1ABAAAC0-F008-4D96-BEB6-FF57BD528360

Q37734245-3907CB4E-2079-468D-B3CD-F529287F0823

Q37734245-537F15C4-670D-461F-B51F-4397380BA5A3

Q37734245-541F5852-BC72-44EA-8092-52B2BC91B097

Q37734245-5DB7A72D-AD8B-4534-8CC9-9AB46CCF1B1F

Q37734245-62D384DF-874E-46EE-990E-9AC6A9B841C7

Q37734245-6D9045A2-06B4-46D5-8B1B-03BC7A9FFC24

Q37734245-9D8826AE-6FA6-4EEF-B587-C8A8218C7919

P304

Q37734245-8CA9CD21-F067-4193-9DEE-AD7085F88A5B

P31

Q37734245-260148E3-25D9-4C38-87B8-769767A4848D

P356

Q37734245-4E9562B2-0C11-44D4-BEE1-5D985B9BCBEB

P433

Q37734245-A55C1BF1-181B-4723-B8FE-89078BD7C25A

P478

Q37734245-CB8789C4-92AB-4A59-8465-85CDB49EAEC1

P577

Q37734245-5E0A3787-71EB-446E-9623-C4F310758FEB

P698

Q37734245-92F09BD3-B67E-4902-B6FB-EBE10901EF45

P932

Q37734245-C90D4317-7ABE-41CD-9014-92866A64DA44

P356

P1433

Journal of clinical and diagnostic research JCDR

P1476

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.

@en

P2093

Ajay Halwai

http://www.w3.org/2001/XMLSchema#string

Basant Maheshwari

http://www.w3.org/2001/XMLSchema#string

Manju Agarwal

http://www.w3.org/2001/XMLSchema#string

Onkar Khandwal

http://www.w3.org/2001/XMLSchema#string

Rajesh Hishikar

http://www.w3.org/2001/XMLSchema#string

Raka Sheohare

http://www.w3.org/2001/XMLSchema#string

Shikha Jaiswal

http://www.w3.org/2001/XMLSchema#string

Usha Joshi

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

LPI-labile plasma iron in iron overload.

Clinical application of deferasirox: practical patient management.

Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

P304

FC01-FC03

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7860/JCDR/2017/22650.9395

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28384880

http://www.w3.org/2001/XMLSchema#string

P932

5376891

http://www.w3.org/2001/XMLSchema#string